Safety and efficacy of targeted alpha therapy with 213Bi-DOTA-substance P in recurrent glioblastoma.

Leszek KrólickiFrank BruchertseiferJolanta KunikowskaHenryk KoziaraBartosz KrólickiMaciej JakucińskiDariusz PawlakChristos ApostolidisSaed MirzadehRafał RolaAdrian MerloAlfred Morgenstern

Published in: European journal of nuclear medicine and molecular imaging (2018)

Treatment of recurrent GBM with 213Bi-DOTA-SP is safe and well tolerated. The median overall survival after recurrence of 10.9 months compares favorably to the available alternative treatment options. Once the supply of high activity 225Ac/213Bi radionuclide generators is secured, targeted alpha therapy with 213Bi-DOTA-SP may evolve as a promising novel option to treat recurrent GBM.

Keyphrases

pet ct
pet imaging
cancer therapy
stem cells
computed tomography
replacement therapy
bone marrow
drug delivery
positron emission tomography
smoking cessation